98901-73-6Relevant academic research and scientific papers
Benzofuran derivatives as potent, orally active S1P1 receptor agonists: A preclinical lead molecule for MS
Saha, Ashis K.,Yu, Xiang,Lin, Jian,Lobera, Mercedes,Sharadendu, Anurag,Chereku, Srinivas,Schutz, Nili,Segal, Dalia,Marantz, Yael,McCauley, Dilara,Middleton, Scot,Siu, Jerry,Burli, Roland W.,Buys, Janet,Horner, Michelle,Salyers, Kevin,Schrag, Michael,Vargas, Hugo M.,Xu, Yang,McElvain, Michele,Xu, Han
, p. 97 - 101 (2011)
We have discovered novel benzofuran-based S1P1 agonists with excellent in vitro potency and selectivity. 1-((4-(5-Benzylbenzofuran-2-yl)-3- fluorophenyl)methyl) azetidine-3-carboxylic acid (18) is a potent S1P 1 agonist with >1000× s
Visible light-induced monofluoromethylenation of heteroarenes with ethyl bromofluoroacetate
Yu, Wei,Xu, Xiu-Hua,Qing, Feng-Ling
supporting information, p. 6564 - 6567 (2016/08/09)
Visible light-induced monofluoromethylenation of benzofurans and benzothiophenes with ethyl bromofluoroacetate was developed. This method provided a convenient access to novel α-fluoro-α-heteroarylesters under mild reaction conditions.
S1P RECEPTOR MODULATING COMPOUNDS AND USE THEREOF
-
Page/Page column 53, (2008/06/13)
The present invention relates to compounds of the general formula (I) that have activity as SlP receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate SlP receptor activity. The compounds may be used as immunomodulators, e.g., for treating or preventing diseases such as autoimmune and related immune disorders including systemic lupus erythematosus, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, type I diabetes, uveitis, psoriasis, myasthenia gravis, rheumatoid arthritis, non-glomerular nephrosis, hepatitis, Behcet's disease, glomerulonephritis, chronic thrombocytopenic purpura, hemolytic anemia, hepatitis and Wegner's granuloma; and for treating other conditions.
Synthesis of potent leukotriene A4 hydrolase inhibitors. Identification of 3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acid
Penning, Thomas D.,Russell, Mark A.,Chen, Barbara B.,Chen, Helen Y.,Liang, Chi-Dean,Mahoney, Matthew W.,Malecha, James W.,Miyashiro, Julie M.,Yu, Stella S.,Askonas, Leslie J.,Gierse, James K.,Harding, Elizabeth I.,Highkin, Maureen K.,Kachur, James F.,Kim, Suzanne H.,Villani-Price, Doreen,Pyla, E. Yvonne,Ghoreishi-Haack, Nayereh S.,Smith, Walter G.
, p. 3482 - 3490 (2007/10/03)
Leukotriene B4 (LTB4) is a potent, proinflammatory mediator involved in the pathogenesis of a number of diseases including inflammatory bowel disease, psoriasis, rheumatoid arthritis, and asthma. The enzyme LTA4 hydrolase
